CervoMed Announced Neflamapimod Selected For Inclusion In UK EXPERTS-ALS Platform For Amyotrophic Lateral Sclerosis Based On Targeted Mechanism, Demonstrated Clinical Activity In Neurodegenerative Diseases, And Translational Data In ALS Relevant N...

CervoMed Inc. -1.24%

CervoMed Inc.

CRVO

3.99

-1.24%

CervoMed Announced Neflamapimod Selected For Inclusion In UK EXPERTS-ALS Platform For Amyotrophic Lateral Sclerosis Based On Targeted Mechanism, Demonstrated Clinical Activity In Neurodegenerative Diseases, And Translational Data In ALS Relevant Neurotoxicity Models